Literature DB >> 22461630

Trans-cellular propagation of Tau aggregation by fibrillar species.

Najla Kfoury1, Brandon B Holmes, Hong Jiang, David M Holtzman, Marc I Diamond.   

Abstract

Aggregation of the microtubule associated protein Tau is associated with several neurodegenerative disorders, including Alzheimer disease and frontotemporal dementia. In Alzheimer disease, Tau pathology spreads progressively throughout the brain, possibly along existing neural networks. However, it is still unclear how the propagation of Tau misfolding occurs. Intriguingly, in animal models, vaccine-based therapies have reduced Tau and synuclein pathology by uncertain mechanisms, given that these proteins are intracellular. We have previously speculated that trans-cellular propagation of misfolding could be mediated by a process similar to prion pathogenesis, in which fibrillar Tau aggregates spread pathology from cell to cell. However, there has been little evidence to demonstrate true trans-cellular propagation of Tau misfolding, in which Tau aggregates from one cell directly contact Tau protein in the recipient cell to trigger further aggregation. Here we have observed that intracellular Tau fibrils are directly released into the medium and then taken up by co-cultured cells. Internalized Tau aggregates induce fibrillization of intracellular Tau in these naive recipient cells via direct protein-protein contact that we demonstrate using FRET. Tau aggregation can be amplified across several generations of cells. An anti-Tau monoclonal antibody blocks Tau aggregate propagation by trapping fibrils in the extracellular space and preventing their uptake. Thus, propagation of Tau protein misfolding among cells can be mediated by release and subsequent uptake of fibrils that directly contact native protein in recipient cells. These results support the model of aggregate propagation by templated conformational change and suggest a mechanism for vaccine-based therapies in neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22461630      PMCID: PMC3365982          DOI: 10.1074/jbc.M112.346072

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer's disease pathology.

Authors:  S D Styren; R L Hamilton; G C Styren; W E Klunk
Journal:  J Histochem Cytochem       Date:  2000-09       Impact factor: 2.479

Review 2.  Prions and exosomes: from PrPc trafficking to PrPsc propagation.

Authors:  Isabel Porto-Carreiro; Benoît Février; Sophie Paquet; Didier Vilette; Graça Raposo
Journal:  Blood Cells Mol Dis       Date:  2005 Sep-Oct       Impact factor: 3.039

3.  Propagation of tau pathology in a model of early Alzheimer's disease.

Authors:  Alix de Calignon; Manuela Polydoro; Marc Suárez-Calvet; Christopher William; David H Adamowicz; Kathy J Kopeikina; Rose Pitstick; Naruhiko Sahara; Karen H Ashe; George A Carlson; Tara L Spires-Jones; Bradley T Hyman
Journal:  Neuron       Date:  2012-02-23       Impact factor: 17.173

4.  Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

Authors:  Eliezer Masliah; Edward Rockenstein; Anthony Adame; Michael Alford; Leslie Crews; Makoto Hashimoto; Peter Seubert; Michael Lee; Jason Goldstein; Tamie Chilcote; Dora Games; Dale Schenk
Journal:  Neuron       Date:  2005-06-16       Impact factor: 17.173

Review 5.  Staging of Alzheimer's disease-related neurofibrillary changes.

Authors:  H Braak; E Braak
Journal:  Neurobiol Aging       Date:  1995 May-Jun       Impact factor: 4.673

6.  Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils.

Authors:  J Götz; F Chen; J van Dorpe; R M Nitsch
Journal:  Science       Date:  2001-08-24       Impact factor: 47.728

7.  Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.

Authors:  D Schenk; R Barbour; W Dunn; G Gordon; H Grajeda; T Guido; K Hu; J Huang; K Johnson-Wood; K Khan; D Kholodenko; M Lee; Z Liao; I Lieberburg; R Motter; L Mutter; F Soriano; G Shopp; N Vasquez; C Vandevert; S Walker; M Wogulis; T Yednock; D Games; P Seubert
Journal:  Nature       Date:  1999-07-08       Impact factor: 49.962

8.  Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease.

Authors:  Angela L Guillozet-Bongaarts; Francisco Garcia-Sierra; Matthew R Reynolds; Peleg M Horowitz; Yifan Fu; Tianyi Wang; Michael E Cahill; Eileen H Bigio; Robert W Berry; Lester I Binder
Journal:  Neurobiol Aging       Date:  2004-12-16       Impact factor: 4.673

9.  Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

Authors:  James A R Nicoll; David Wilkinson; Clive Holmes; Phil Steart; Hannah Markham; Roy O Weller
Journal:  Nat Med       Date:  2003-03-17       Impact factor: 53.440

10.  A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor.

Authors:  Sonia K Pollitt; Judit Pallos; Jieya Shao; Urvee A Desai; Aye Aye K Ma; Leslie Michels Thompson; J Lawrence Marsh; Marc I Diamond
Journal:  Neuron       Date:  2003-11-13       Impact factor: 17.173

View more
  251 in total

1.  Beyond amyloid: getting real about nonamyloid targets in Alzheimer's disease.

Authors:  Karl Herrup; Maria C Carrillo; Dale Schenk; Angela Cacace; Susan Desanti; Robert Fremeau; Ratan Bhat; Marcie Glicksman; Patrick May; Russell Swerdlow; Linda J Van Eldik; Lisa J Bain; Samantha Budd
Journal:  Alzheimers Dement       Date:  2013-07       Impact factor: 21.566

Review 2.  Tau immunotherapy and imaging.

Authors:  Einar M Sigurdsson
Journal:  Neurodegener Dis       Date:  2013-09-11       Impact factor: 2.977

3.  Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds.

Authors:  Brandon B Holmes; Sarah L DeVos; Najla Kfoury; Mei Li; Rachel Jacks; Kiran Yanamandra; Mohand O Ouidja; Frances M Brodsky; Jayne Marasa; Devika P Bagchi; Paul T Kotzbauer; Timothy M Miller; Dulce Papy-Garcia; Marc I Diamond
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-29       Impact factor: 11.205

Review 4.  Self-propagation of pathogenic protein aggregates in neurodegenerative diseases.

Authors:  Mathias Jucker; Lary C Walker
Journal:  Nature       Date:  2013-09-05       Impact factor: 49.962

5.  Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology.

Authors:  Jiaping Gu; Erin E Congdon; Einar M Sigurdsson
Journal:  J Biol Chem       Date:  2013-10-02       Impact factor: 5.157

Review 6.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

7.  Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy.

Authors:  Michiyo Iba; Jing L Guo; Jennifer D McBride; Bin Zhang; John Q Trojanowski; Virginia M-Y Lee
Journal:  J Neurosci       Date:  2013-01-16       Impact factor: 6.167

8.  Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.

Authors:  Markus Mandler; Elvira Valera; Edward Rockenstein; Harald Weninger; Christina Patrick; Anthony Adame; Radmila Santic; Stefanie Meindl; Benjamin Vigl; Oskar Smrzka; Achim Schneeberger; Frank Mattner; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2014-02-14       Impact factor: 17.088

Review 9.  Amyotrophic lateral sclerosis--a model of corticofugal axonal spread.

Authors:  Heiko Braak; Johannes Brettschneider; Albert C Ludolph; Virginia M Lee; John Q Trojanowski; Kelly Del Tredici
Journal:  Nat Rev Neurol       Date:  2013-11-12       Impact factor: 42.937

Review 10.  Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.

Authors:  Elvira Valera; Brian Spencer; Eliezer Masliah
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.